Center for Immunology of Emerging Infectious Diseases

新发传染病免疫学中心

• 批准号: 7663373
• 负责人: DONALD SCOTT BURKE
• 金额: $ 64.99万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-28 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7663373
• 关键词: Center; Immunology; Emerging; Infectious; Diseases

Dengue virus (DENV) infection of humans has steadily increased in importance as an emerging infectious disease, and the development of protective vaccines to DENV disease has been impeded by a lack of understanding of virus-specific immune responses and their role in OT. 7"o protection and disease. To address these critical issues related to DENV infection and disease, we have established a unique collaborative consortium, the Center for Immunology of Emerging Infectious Diseases (CIEID) located at the University of Pittsburgh. The focus of the CIEID is to conduct comprehensive analysis of immune responses to DENV virus infection of humans using the unique clinical samples previously obtained from patients in Recife, Brazil, and now archived at the Center for Vaccine Research at the University of Pittsburgh. We will use these samples to characterize the initial role of antigen-presenting cells in DENV immunopathogenesis (Project 1), to define the interaction of T-Iymphocytes with dendritic cells in the progression of immunity --. `". man <C) 0007 .O- (3p =!! and disease (Project 2), and to define how DENV suppresses innate immune responses to DENV infection (Project 3). These translational immunology studies will be supported by a combined administrative and clinical core. It is anticipated that the results of the proposed studies will produce important new insights into the role of DENy-specific immunity in infection and disease that can then inform strategies for treatment and vaccine development. It is also expected that the CIEID will provide platform technologies and comprehensive expertise in translational immunology that can readily be applied to other emerging infectious diseases or 3-6 m_3 0-3 ti. (OD biodefense pathogens.

登革病毒(DENV)对人类的感染作为一种新兴的 由于缺乏对病毒特异性免疫反应及其在疾病中的作用的了解，DENV疾病的保护性疫苗的开发受到了阻碍。 不是的。 7“o 保护和疾病。为了解决这些与DENV感染和疾病相关的关键问题，我们成立了一个独特的合作联盟，位于匹兹堡大学的新发传染病免疫学中心(CIEID)。CIEID的重点是使用以前从巴西累西腓患者那里获得的独特临床样本，现在匹兹堡大学疫苗研究中心存档，对人类对DENV病毒感染的免疫反应进行全面分析。我们将利用这些样本来表征抗原提呈细胞在DENV免疫发病中的初始作用(项目1)，以确定T淋巴细胞与树突状细胞在免疫进展中的相互作用 -- `“。 男人 &lt；C) 0007 .o- (3页) =！！ 和疾病(项目2)，并确定DENV如何抑制对DENV感染的先天性免疫反应(项目3)。这些转译免疫学研究将得到管理和临床核心的支持。预计拟议研究的结果将对拒绝特异性免疫在感染和疾病中的作用产生重要的新见解，从而为治疗和疫苗开发战略提供参考。还预计CIEID将提供翻译免疫学的平台技术和全面的专业知识，这些技术和专业知识可随时应用于其他新出现的传染病或 三六 M_3 0-3 天哪。 (OD 生物防御病原体。